<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)
COPLEY PHARMACEUTICAL, INC.
___________________________________________________________
(Name of Issuer)
Common Stock, par value $.01 per share
___________________________________________________________
(Title of Class of Securities)
21745K-10-1
_________________________________________________
(CUSIP Number)
Julie K. Chapin, Esq. David A. Jenkins
Associate General Counsel President
Hoechst Corporation Hoechst Corporation
30 Independence Boulevard 86 Morris Avenue
P.O. Box 4915 Summit, NJ 07901
Warren, NJ 07060-4915
(908) 231-2689 (908) 231-4058
________________________________________________________________________________
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 17, 1999
_____________________________________________________________
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with this statement [ ].
<PAGE>
CUSIP No. 2174445k-10-1 2
_______________________________________________________________________________
1) Name of Reporting Person and its Hoechst Corporation
I.R.S. Identification Number 22-1862783
_______________________________________________________________________________
2) Check the Appropriate Box if (a) [ ]
a Member of a Group (b) [ ]
_______________________________________________________________________________
3) SEC Use Only
_______________________________________________________________________________
4) Source of Funds Not applicable
_______________________________________________________________________________
5) Check Box if Disclosure of Legal
Proceedings is Required Pursuant
to Items 2(d) or 2(e) [ ]
_______________________________________________________________________________
6) Citizenship or Place of Organization Delaware
_______________________________________________________________________________
7) Sole Voting Power 9,934,100
Number of ___________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ___________________________________________________________
Each
Reporting 9) Sole Dispositive Power 9,934,100
Person With ___________________________________________________________
10) Shared Dispositive Power 0
_______________________________________________________________________________
11) Aggregate Amount Beneficially Owned
by Each Reporting Person 9,934,100
_______________________________________________________________________________
12) Check Box If the Aggregate Amount
in Row (11) Excludes Certain Shares [ ]
_______________________________________________________________________________
13) Percent of Class Represented
by Amount in Row (11) 52.9%
_______________________________________________________________________________
14) Type of Reporting Person CO
<PAGE>
This Amendment to the Statement on Schedule 13D (the "Schedule 13D") with
respect to the Common Stock of Copley Pharmaceutical, Inc. (the "Issuer") is
filed by Hoechst Corporation, a Delaware corporation ("Parent").
ITEM 2. IDENTITY AND BACKGROUND
- ---------------------------------
Hoechst Corporation
Delaware
Holding Company
30 Independence Boulevard
Warren, New Jersey 07059
Effective May 17, 1999, HCCP Acquisition Corporation, a Delaware
corporation ("Acquisition"), and the direct beneficial owner of the securities
of the Issuer, merged with and into Parent pursuant to the provisions of Section
253 of the Delaware General Corporation Law. As a result of the merger,
Acquisition ceased to exist and Parent became the direct beneficial owner of the
securities of the Issuer.
ITEM 4. PURPOSE OF TRANSACTION.
- ---------------------------------
Item 4 is hereby amended to add the following:
Parent continuously reviews its investments, including its investment in
the Issuer, as set forth in Amendment No. 5 to this Statement on Schedule
13D. As part of this process Parent is continuing to evaluate divestiture
options for its holdings of securities of the Issuer.
ITEM 5. INTEREST IN SECURITIES OF ISSUER
- ------------------------------------------
(a) The shares represent approximately 52.9 percent of the Issuer's common
stock outstanding at April 27, 1999. Neither Parent nor any executive
officer or director of Parent beneficially owns any other shares of Common
Stock.
(b) Parent has the sole power to vote and the sole power to dispose of the
Shares. Neither any executive officer nor director of Parent has any power
to vote or to direct the vote or to dispose or to direct the disposition
of, the Shares except to the extent that any such executive officer or
director may be deemed to have any such power by reason of such person's
relationship to or position with Parent.
(c) On May 17, 1999, Acquisition merged with and into Parent, as a result
of which Acquisition ceased to exist and Parent is now the direct
beneficial owner of the Shares.
(d) None
(e) Not applicable
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
HOECHST CORPORATION
/c/ David A. Jenkins
_____________________________
By: David A. Jenkins
President & General Counsel
Date: May 17, 1999
